Managed Markets
Network

Journals

MORE >>>
Clinical Outcomes and Healthcare Use Associated With Optimal ESRD Starts
September 26, 2018 – Peter W. Crooks, MD; Christopher O. Thomas, MD; Amy Compton-Phillips, MD; Wendy Leith, MS, MPH; Alvina Sundang, MBA; Yi Yvonne Zhou, PhD; and Linda Radler, MBA
Opportunities and Challenges in Biosimilar Uptake in Oncology
June 26, 2018 – Carina Dolan, PharmD, BCOP
Development and Implementation of an Academic Cancer Therapy Stewardship Program
March 15, 2018 – Amir S. Steinberg, MD; Anish B. Parikh, MD; Sara Kim, PharmD; Damaris Peralta-Hernandez, RPh; Talaat Aggour, BPharm; and Luis Isola, MD

Study Summaries

Study Summary: Cabozantinib for Advanced and Progressing Hepatocellular Carcinoma
November 09, 2018
Study Summary: Use of Enzalutamide for High-Risk, Nonmetastatic, Castration-Resistant Prostate Cancer (PROSPER)
November 08, 2018
Study Summary: Osimertinib Versus Standard EGFR-TKI Therapy in Patients With EGFR-Mutated Advanced NSCLC and Brain Metastases at Baseline
November 08, 2018
Study Summary: Abemaciclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive, Endocrine-Refractory, Advanced Breast Cancer (MONARCH 2)
September 24, 2018
Study Summary: Abemaciclib as Initial Therapy in Patients With Advanced Breast Cancer (MONARCH 3)
September 24, 2018
Study Summary: Abemaciclib Monotherapy in Patients With Hormone Receptor-Positive, Endocrine-Refractory, Metastatic Breast Cancer (MONARCH-1)
September 24, 2018
ACCOUNTABLE CARE DELIVERY CONGRESS
CONTINUING EDUCATION
CONTRIBUTORS
MEETINGS
PARTICIPATE
COMPENDIA
In Focus Blog
Press Releases
Interactive Tools
Managed Care Podcast
Panel Discussions
Week In Review
Information for Reviewers
Information for Authors
Formulary Central
Clinical Study Summaries
Study Summaries
About Us
AJAC
AJMC
EBDM
EBO
AJMC Resources
Careers
Contact Us
Privacy Policy
Terms & Conditions
Subscribe
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
×

Sign In

Not a member? Sign up now!